The first randomized outcome trial to test Lp(a) lowering drugs has failed to show any benefit at reducing heart attacks and strokes (MACE).
We only have a topline press announcement from Novartis at this point, but nevertheless, this result is going to seriously call into question the assumption that Lp(a) is directly causal in heart disease.
NovartisNovartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)novartis.com
Quoted from the press release:
“Although lower Lp(a) levels were observed with pelacarsen, the findings did not demonstrate that this translated into reduced cardiovascular risk in the overall study population. These are not the results we hoped for, but they provide important evidence that advances scientific understanding of the relationship between Lp(a) lowering and cardiovascular outcomes and may help inform future approaches to cardiovascular risk management.”


